The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell response

Simple item page
dc.contributor.authorKagina, Benjamin M.N.
dc.contributor.authorTameris, Michele D.
dc.contributor.authorHussey, Gregory D.
dc.contributor.authorBenko, Jacqueline
dc.date.accessioned2023-02-15T19:03:59Z
dc.date.available2023-02-15T19:03:59Z
dc.date.issued2014
dc.description.abstractEfforts to reduce risk of tuberculosis disease in children include development of effective vaccines. Our aim was to test safety and immunogenicity of the new adenovirus 35-vectored tuberculosis vaccine candidate AERAS-402 in infants, administered as a boost following a prime with the Bacille Calmette-Guerin vaccine. In a phase 1 randomised, double-blind, placebo-controlled, dose-escalation trial, BCG-vaccinated infants aged 6–9 months were sequentially assigned to four study groups, then randomized to receive an increasing dose-strength of AERAS-402, or placebo. The highest dose group received a second dose of vaccine or placebo 56 days after the first. The primary study outcome was safety. Whole blood intracellular cytokine staining assessed immunogenicity. Forty-two infants received AERAS-402 and 15 infants received placebo. During follow-up of 182 days, an acceptable safety profile was shown with no serious adverse events or discontinuations related to the vaccine. AERAS-402 induced a specific T cell response. A single dose of AERAS-402 induced CD4T cells predominantly expressing single IFN-γ whereas two doses induced CD4T cells predominantly expressing IFN-γ, TNF-α and IL-2 together. CD8T cells were induced and were more likely to be present after 2 doses of AERAS-402. AERAS-402 was safe and immunogenic in healthy infants previously vaccinated with BCG at birth. Administration of the highest dose twice may be the most optimal vaccination strategy, based on the induced immunity. Multiple differences in T cell responses when infants are compared with adults vaccinated with AERAS-402, in the same setting and using the same whole blood intracellular cytokine assay, suggest specific strategies may be important for vaccination for each population.en_US
dc.identifier.citationKagina, B. M., Tameris, M. D., Geldenhuys, H., Hatherill, M., Abel, B., Hussey, G. D., ... & Hokey, D. A. (2014). The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine, 32(45), 5908-5917.https://doi.org/10.1016/j.vaccine.2014.09.001en_US
dc.identifier.issn0264-410X
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/7807
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectTuberculosis vaccinesen_US
dc.subjectBCGen_US
dc.subjectAERAS-402en_US
dc.subjectVaccine-induced T cell immunityen_US
dc.subjectInfantsen_US
dc.titleThe novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responseen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.pdf
Size:
2.34 MB
Format:
Adobe Portable Document Format
Description:
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences